Recent News

• 09.15.2025 - Quest Diagnostics to Speak at the Jefferies Healthcare Services Conference
• 09.04.2025 - Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering
• 09.02.2025 - Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index
• 08.26.2025 - Corewell Health and Quest Diagnostics to Enter into Joint Venture Providing Enhanced Laboratory Services in Michigan
• 08.25.2025 - FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics
• 08.15.2025 - Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference
• 08.13.2025 - Quest Diagnostics Declares Quarterly Cash Dividend
• 08.07.2025 - Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types
• 08.05.2025 - Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care

Recent Filings

• 08.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.21.2025 - 144 Report of proposed sale of securities
• 08.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.19.2025 - 144 Report of proposed sale of securities
• 08.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.15.2025 - 144 Report of proposed sale of securities
• 08.15.2025 - 144 Report of proposed sale of securities
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.08.2025 - 4 Statement of changes in beneficial ownership of securities